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The class III histone deacetylase sirtuin 6 (SIRT6) modulates
numerous functions in the cell by deacetylating histone lysine
residues. Interestingly, SIRT6’s efficiency in in vitro experi-
ments is far greater against substrates carrying long-chain fatty
acyl modifications such as myristoylated lysine compared with
acetylated counterparts, but the deacetylase activity can be
stimulated by fatty acids and small-molecule allosteric modula-
tors. A new study helps to explain this puzzling activation using
a novel activator, thorough kinetic investigation, and mutagen-
esis studies. These data help elucidate the molecular require-
ments for activation of SIRT6 and provide a foundation for
development of activators for therapeutic purposes.
The sirtuins comprise a family of seven NAD-dependent
lysine deacylase enzyme isoforms (SIRT1–7). Each family
member has distinct cellular roles and subcellular localization,
with SIRT6 primarily located to the nucleus, where it partici-
pates in chromatin remodeling, cleaving acetyl groups from the
side chains of acetylated lysine residues in histone proteins.
However, it has been shown that SIRT6 can also exhibit ADP-
ribosyl transferase activity as well as deacetylase activity against
nonchromatin targets that are involved in a plethora of biolog-
ical functions, such as DNA repair, glucose homeostasis, and
aging (1, 2). Overexpression of SIRT6 has beneficial health out-
comes, suggesting that a greater understanding of its role and
function—and the corresponding ability to modulate those
functions—would be useful. A new study by Klein et al. (3)
provides important advances on these fronts, developing new
small molecules and mutated variants to explore and manipu-
late SIRT6 activity, establishing new steps in SIRT6’s catalytic
mechanism, and identifying unique aspects of this mechanism
that delineate it from other sirtuin isoforms.
Investigating SIRT6 has been challenging in part because its
activity in vitro does not mirror known cellular functions: In
enzyme assays, long-chain acyl substrates (e.g. -N-myristoyl-
lysine, Kmyr) are deacylated 100-fold faster than analogous
acetylated substrates (4, 5). SIRT6 protein structures have
shown that this is due to the existence of a hydrophobic cavity
that extends the binding site, matching well with the longer-
chain molecules (Fig. 1). However, Denu and co-workers (5)
previously discovered that fatty acids can boost the deacetylase
activity of SIRT6 by occupying the hydrophobic cavity. This
suggested that endogenous activators of SIRT6 might increase
its deacetylase activity in vivo and also that it might be possible
to identify novel SIRT6 activators to further investigate ormod-
ulate SIRT6. Recently, small-molecule activators have also been
developed by the groups of Steegborn (6) and Zhang (7). The
compound developed in the latter mentioned study was shown
to bind in an allosteric pocket above the distal part of the hydro-
phobic cavity (Fig. 1). Additionally, a prodrug version of the
compound was found to regulate SIRT6 function in cells and is
now commercially available as a probe compound. However,
the mechanism and kinetic parameters of SIRT6 activation
were not investigated in great detail in those reports and remain
poorly understood.
To gain further insight into these questions, Denu and co-
workers (3) report a deep dive into the mechanism of SIRT6,
enabled by the discovery of novel SIRT6 activators and a critical
mutant construct. The authors first use activity-based screen-
ing of several compound libraries of fatty acids and aromatic
carboxylates to look for novel activators that could enhance
SIRT6 deacetylation, identifying several hits that increased
activity up to 312-fold. Subsequent chemical derivatization of
one of the hit compounds furnished the design of a highly
potent activator, CL5D. Also, CL5D failed to increase long-
chain deacylase activity, but was rather found to competi-
tively inhibit SIRT6 demyristoylation, suggesting that it
binds in the same hydrophobic pocket as observed for fatty
acid activators (5).
In efforts to identify the crucial residues that are critical for
the catalytic enhancement of SIRT6 deacetylation activity, a
number of SIRT6 variants with mutated arginine or lysine res-
idues positioned at diverse locations in the protein were
expressed and evaluated. Themutation ofArg-65 toAla (R65A)
resulted in an enzyme that retained base-level deacetylase
activity but failed to be activated by CL5D and exhibited dras-
tically reduced demyristoylase activity. Elaborate kinetic profil-
ing of both WT enzyme and R65A mutant uncovered that
SIRT6 activators enhance deacetylation by boosting a rate-
determining catalytic step after substrate binding but prior to
the release of nicotinamide (the first irreversible step in SIRT-
mediated hydrolysis), which the authors attribute to a slow con-
formational change after ruling out known chemical steps. The
R65A mutant was previously found to hamper SIRT6 deacety-
lation of cellular targets (8), but themechanismwas not known.
In the context of the new data from Klein et al., this result
strongly suggests that Arg-65 assists in the in vivo efficacy of
SIRT6 and that endogenous modulators likely serve an impor-
tant role in activating the enzyme in a cellular context.
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Overall, this study addresses the possible functional differ-
ences between the behavior of an enzyme in vitro versus its
native environment in the cell. It is likely that other sirtuin
enzymes have similar endogenous activation mechanisms. For
example, the relatively unexplored family member SIRT7 has
been shown to undergo co-activation by oligonucleotides to
enhance its activity in vitro (9). Recently, it was shown that
using entire nucleosome particles as substrates might provide a
more accurate measurement of the activity of SIRT7 (10), and,
in turn, it was also speculated that the same might be true for
SIRT6 (10). Thus, cellular interaction partners might serve a
crucial role in activation of sirtuin enzymes. It is possible that
endogenous activators may provide regulatory mechanisms.
For example, the sirtuin enzymes may act as sensors and only
initiate hydrolysis upon certain changes in the cellular environ-
ment (e.g. by changes in chromatin structure or fatty acid
concentration).
In future studies, the use of SIRT6 activatorsmight be imple-
mented and standardized for improved assay conditions so that
the conditions used in biochemical assays better resemble a
physiologically relevant environment. It is likely that additional
endogenous interaction partners and activators will be discov-
ered for sirtuins and histone deacetylases and that the enzy-
matic activity for other sirtuin enzymes might likewise be
greatly impacted by the discovery of novel activators. With the
advances in molecular-resolution imaging techniques and in
cryo-EM, it might soon be possible to investigate conforma-
tional changes during sirtuin enzyme catalysis. Techniques like
these might also help reveal additional sirtuin interaction part-
ners and help explore novel endogenous modulators.
Activators of SIRT1, and sirtuin inhibitors in general, have
been extensively explored, but the therapeutic potential of
SIRT6 activators remains relatively unknown. Development of
selective sirtuin inhibitors has been challenging due to the com-
mon NAD-dependent deacylase mechanism and overlap in
substrate recognition between sirtuin isozymes, meaning that
activators that bind allosterically might hold more promise for
achieving selective perturbation of individual sirtuin subtypes.
Additionally, as other SIRT6 activators bind allosterically to the
enzyme, it will be interesting to explore whether the use of
activator combinations can synergistically enhance deacetylase
activity even further. It will be interesting to follow the discov-
ery of novel activators of both SIRT6 and other sirtuins/histone
deacetylases in the future, which may lead to deeper under-
standing of the cellular function of these hydrolases and ulti-
mately form the basis for development of new therapeutics.
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Figure1.Slice viewofSIRT6co-crystalizedwithmyristoylatedhistoneH3
Lys-9–derived substrate (cyan) and ADP-ribose (yellow) (Protein Data
Bank entry 3ZG6). The additional color coding highlights the hydrophobic
cavity of the substrate-binding site (blue), the NAD-binding pocket (beige),
the allosteric activation site (magenta), and theArg-65 (R65; in red space-filling
format). This residue is positioned above the NAD-binding pocket and
makesextensivepolar andelectrostatic interactionswith the riboseandpyro-
phosphate of ADPR in the co-crystal structure.
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